Scarica l'app Stockscreener
748.04
0.34%
-2.5698
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$750.61
Aprire:
$748.09
Volume 24 ore:
1.32M
Relative Volume:
0.31
Capitalizzazione di mercato:
$708.21B
Reddito:
$53.26B
Utile/perdita netta:
$13.80B
Rapporto P/E:
48.89
EPS:
15.3
Flusso di cassa netto:
$-50.20M
1 W Prestazione:
+1.39%
1M Prestazione:
+19.57%
6M Prestazione:
-9.84%
1 anno Prestazione:
-16.99%
Intervallo 1D:
$742.49
$752.09
Intervallo di 1 settimana:
$719.22
$752.84
Portata 52W:
$623.78
$942.35
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
748.28 | 662.16B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
175.35 | 429.00B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
211.39 | 370.61B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.48 | 249.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.07 | 210.04B | 63.43B | 16.42B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Sept 2025) - 24/7 Wall St.
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets - Benzinga
Wegovy and Ozempic maker to cut 9,000 jobs amid stiff competition from Eli Lilly - Yahoo Finance
Novo Tries To Catch Up With Lilly By Slashing 11% Of Workforce - NDTV Profit
Novo Tries to Catch Up With Lilly by Slashing 11% of Workforce - Bloomberg.com
Eli Lilly launches AI-powered drug development platform for biotech operators - Mugglehead Magazine
Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies - Yahoo Finance
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' - Benzinga
Defiance Has A New ETF For High-Stakes Pharma Traders - Benzinga
Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’ - Stocktwits
Eli Lilly (LLY) Announces New AI Platform to Accelerate Drug Discoveries - TipRanks
Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data - Benzinga
Lilly launches AI-powered platform to accelerate drug discovery - Reuters
Eli Lilly launches AI platform for drug discovery - Proactive financial news
Lilly looks into gene therapies for obesity - statnews.com
Lilly launches AI platform TuneLab for biotech firms (LLY:NYSE) - Seeking Alpha
Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health - Eli Lilly
Eli Lilly and Co launches the TuneLab platform, opening AI drug discovery models to biotechnology companies. - 富途牛牛
Eli Lilly (LLY) Launches AI-Powered Drug Discovery Platform - GuruFocus
Lilly launches AI platform for biotechs with $1 billion worth of data - Investing.com
Eli Lilly Launches $1 Bln AI Drug Discovery Platform TuneLab - Nasdaq
Eli Lilly launches platform for AI-enabled drug discovery - Reuters
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment - Eli Lilly
$1 Billion Worth of Drug Discovery Data: Eli Lilly Shares AI Models to Revolutionize Biotech Research - Stock Titan
Alchemab starts first-in-human study of Lilly-partnered antibody, pockets $32M - FirstWord Pharma
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Eli Lilly (LLY) Announces Promising Results For Jaypirca In CLL Phase 3 Trial - simplywall.st
Ozempic Is The New BotoxAnd Novo, Eli Lilly Are Printing BillionsNovo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly succeeds in late-stage leukemia treatment trial (LLY:NYSE) - Seeking Alpha
Lilly’s pirtobrutinib shows strong results in front-line CLL study - Investing.com
Eli Lilly’s Jaypirca meets primary endpoint in leukemia trial By Investing.com - Investing.com South Africa
Eli Lilly’s Jaypirca meets primary endpoint in leukemia trial - Investing.com
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL - Eli Lilly and Company
Inside Eli Lilly’s Cork plant making key ingredient for Mounjaro weight-loss drug - Irish Examiner
No more needles — a weight-loss pill is on its way to Britain - The Times
Lilly, Novo Sink on FDA List of Foreign GLP-1 Manufacturers - MSN
Lilly, Novo Sink on FDA List of Foreign GLP-1 Ingredient Makers - Bloomberg
Advanced analytics toolkit walkthrough for Eli Lilly and Company2025 Institutional Moves & Daily Stock Momentum Reports - Newser
Eli Lilly (LLY) Faces FDA Crackdown on Compounded GLP-1 Drugs - GuruFocus
Eli Lilly and Company Stock (LLY) Opinions on Recent Drug Trial Results - Quiver Quantitative
Lila Biologics, Eli Lilly partner for radioligand therapies - Mobi Health News
Lila Biologics, Eli Lilly team up for radioligand therapies - Mobi Health News
Eli Lilly Will Soon Ask Regulators To Approve Its Weight-Loss Pill. Is It Now A Buy? - Investor's Business Daily
Eli Lilly’s (LLY) Lung Cancer Drug Given ‘Breakthrough Therapy’ Designation - TipRanks
Jefferies Sees Huge Potential in Eli Lilly’s (LLY) New Weight-Loss Pill - uk.finance.yahoo.com
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day? - AOL.com
Lilly-Merck Combo Drug For Lung Cancer Receives FDA Breakthrough StatusEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (LLY) Gains Breakthrough Therapy Designation For Advanced Lung Cancer Treatment - simplywall.st
Lila Biologics Spins Out of Baker Lab, Announces Lilly Collaboration - Inside Precision Medicine
Startup spun out of Nobel Laureate’s lab teams with Eli Lilly to fight cancer with AI - GeekWire
Type 1 Diabetes Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer - Barchart.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lilly Eli Co Azioni (LLY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zakrowski Donald A | SVP, Finance, & CAO |
Aug 28 '25 |
Sale |
734.93 |
1,000 |
734,930 |
3,840 |
| Montarce Lucas | EVP & CFO |
Aug 15 '25 |
Buy |
691.79 |
715 |
494,627 |
14,685 |
| Alvarez Ralph | Director |
Aug 13 '25 |
Buy |
660.25 |
758 |
500,473 |
758 |
| Van Naarden Jacob | EVP & Pres., Lilly Oncology |
Aug 13 '25 |
Buy |
647.36 |
1,000 |
647,360 |
20,562 |
| Ricks David A | President, Chair, and CEO |
Aug 12 '25 |
Buy |
644.77 |
1,632 |
1,052,263 |
546,601 |
| Skovronsky Daniel | EVP, CSO & Pres. LRL & LLY Imm |
Aug 12 '25 |
Buy |
634.40 |
1,000 |
634,405 |
137,660 |
| Sulzberger Gabrielle | Director |
Aug 12 '25 |
Buy |
641.18 |
117 |
75,018 |
2,703 |
| Fyrwald J Erik | Director |
Aug 12 '25 |
Buy |
642.33 |
1,565 |
1,005,242 |
74,578 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Aug 11 '25 |
Sale |
627.01 |
1,250 |
783,762 |
26,260 |
| JACKSON JAMERE | Director |
Aug 08 '25 |
Buy |
639.56 |
200 |
127,913 |
9,402 |
0.96%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):